Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894368 | 0.94 | TP53 (0.45) | TP53MAPTLMNACHEK1PDPK1 | |
| SCHEMBL4888758 | 0.92 | ITGB3 (0.42) | CHEK1PDPK1CDK1AURKAAURKB | |
| SCHEMBL5189501 | 0.89 | ITK (0.45) | TP53MAPTCHEK1PDPK1CDK1 | |
| SCHEMBL4889015 | 0.86 | AURKA (0.43) | CHEK1PDPK1CDK1AURKAAURKB | |
| SCHEMBL5954096 | 0.86 | ITGB3 (0.44) | CHEK1PDPK1MEN1KMT2ACDK1 | |
| SCHEMBL4896780 | 0.86 | ITK (0.47) | CHEK1PDPK1CDK1AURKAAURKB | |
| SCHEMBL4880110 | 0.85 | ITK (0.46) | CHEK1PDPK1CDK1AURKAAURKB | |
| SCHEMBL4891211 | 0.84 | ITK (0.45) | CHEK1PDPK1CDK1AURKAAURKB | |
| SCHEMBL4130802 | 0.84 | AURKA (0.61) | TP53MAPTLMNAMEN1KMT2A | |
| SCHEMBL4889880 | 0.84 | AURKA (0.41) | LMNACHEK1PDPK1CDK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2008524151-A | — | — | 2008-07-10 | — | — | JP | claimed |
| CN-101080408-A | Trycyclic heterocycles, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | claimed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | claimed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| CN-101080408-A | Trycyclic heterocycles, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142247-A1 | Tricyclic heterocycles | CYP11B1, CYP11B2, CYP3A43 | TP53 172/4885MAPT 4241/4885LMNA 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.